7.9
"MindMed Earns FDA Breakthrough Designation for MM120; Successful Phase 2B Trial Shows Promising 12-week Sustained Relief for Generalized Anxiety Disorder"
businesswire.com
#
©
News Score
score the news, sort the news, rewrite the headlines
Leaderboard
Submit
About